ABBV Research Update — August 28, 2026
Updated Thesis
AbbVie is a diversified global biopharma company spanning immunology, neuroscience, oncology and aesthetics, with a high-quality commercial platform, strong intangible assets and leading franchises in Skyrizi and Rinvoq. Business momentum is solid: Q2 2026 revenue rose 10.2% year over year to $16.99 billion, driven by 24.4% Skyrizi growth and 24.5% Rinvoq growth, while TTM gross and operating margins were 71.5% and 29.3%, respectively. However, the post-Humira transition remains incomplete, with Humira revenue down 35.9% and Imbruvica down 29% in Q2, and the shares trade at 72.37x trailing earnings, 23.22x free cash flow and 24.49x EV/EBITDA.
The investment grade as of this refresh is C — average business quality. High-tier business, very expensive-tier valuation, with 7.5% downside to $238.76 fair value.
Key Metrics at a Glance
- Revenue growth: +10.2% year over year
- Net margin: 9.8%
- Fair value upside: -7.5% to our estimate of $239
Current price: $258.02
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. AbbVie Inc. remains in our covered universe with a average-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full ABBV research →](/stocks/ABBV)